CERES BRAIN Therapeutics, a spin-off from the renowned French academic center CEA, is pioneering the development of groundbreaking products designed to supply brain neurons with creatine. Creatine, a natural molecule with crucial brain properties, is key in maintaining energy homeostasis, protecting neurons, and facilitating neuromodulation and neurotransmission. In response, Ceres has developed the creatine-to-neurons™ solution, exemplified by its leading drug candidate, CBT101. CBT101 is currently the only drug capable of delivering creatine to neurons. Ceres has substantiated the efficacy of CBT101 through various animal experiments, demonstrating significant biological, metabolic, and clinical improvements in relevant models, including SLC6A8-KO mice, rats with mitochondriopathy, and monkeys utilizing labelled creatine.